Evangelia Liouta, Aristotelis V Kalyvas, Spyridon Komaitis, Evangelos Drosos, Christos Koutsarnakis, Juan M García-Gómez, Javier Juan-Albarracín, Vasileios Katsaros, Theodosis Kalamatianos, Theodoros Argyrakos, George Stranjalis
{"title":"高级别胶质瘤患者术前神经认知状态与IDH1突变状态的关系","authors":"Evangelia Liouta, Aristotelis V Kalyvas, Spyridon Komaitis, Evangelos Drosos, Christos Koutsarnakis, Juan M García-Gómez, Javier Juan-Albarracín, Vasileios Katsaros, Theodosis Kalamatianos, Theodoros Argyrakos, George Stranjalis","doi":"10.1093/nop/npac077","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>High-grade glioma (HGG) patients present with variable impairment in neurocognitive function (NCF). Based on that, isocitrate dehydrogenase 1 (IDH1) wild-type HGGs are more aggressive than IDH1 mutant-type ones, we hypothesized that patients with IDH1 wild-type HGG would exhibit more severe NCF deficits than their IDH1 mutant counterparts.</p><p><strong>Methods: </strong>NCF was assessed by Mini Mental Status Exam (MMSE), Trail Making Test (TMT), Digit Span (DS), and Controlled Word Association Test (COWAT) tests in 147 HGG patients preoperatively.</p><p><strong>Results: </strong>Analyses between IDH1 groups revealed a significant difference on MMSE concentration component (<i>p</i> ≤ .01), DS (<i>p</i> ≤ .01), TMTB (<i>p</i> ≤ .01), and COWAT (<i>p</i> ≤ .01) scores, with the IDH1 wild group performing worse than the IDH1 mutant one. Age and tumor volume were inversely correlated with MMSE concentration component (<i>r</i> = -4.78, <i>p</i> < .01), and with MMSE concentration (<i>r</i> = -.401, <i>p</i> < .01), TMTB (<i>r</i> = -.328, <i>p</i> < .01), and COWAT phonemic scores (<i>r</i> = -.599, <i>p</i> < .01), respectively, but only for the IDH1 wild-type group. Analyses between age-matched subsamples of IDH1 groups revealed no age effect on NCF. Tumor grade showed nonsignificance on NCF (<i>p</i> > .05) between the 2 IDH1 mutation subgroups of grade IV tumor patients. On the contrary, grade III group showed a significant difference in TMTB (<i>p</i> < .01) and DS backwards (<i>p</i> < .01) between IDH1 subgroups, with the mutant one outperforming the IDH1 wild one.</p><p><strong>Conclusions: </strong>Our findings indicate that IDH1 wild-type HGG patients present greater NCF impairment, in executive functions particularly, compared to IDH1 mutant ones, suggesting that tumor growth kinetics may play a more profound role than other tumor and demographic parameters in clinical NCF of HGG patients.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 2","pages":"132-139"},"PeriodicalIF":2.4000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037936/pdf/","citationCount":"2","resultStr":"{\"title\":\"Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas.\",\"authors\":\"Evangelia Liouta, Aristotelis V Kalyvas, Spyridon Komaitis, Evangelos Drosos, Christos Koutsarnakis, Juan M García-Gómez, Javier Juan-Albarracín, Vasileios Katsaros, Theodosis Kalamatianos, Theodoros Argyrakos, George Stranjalis\",\"doi\":\"10.1093/nop/npac077\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>High-grade glioma (HGG) patients present with variable impairment in neurocognitive function (NCF). Based on that, isocitrate dehydrogenase 1 (IDH1) wild-type HGGs are more aggressive than IDH1 mutant-type ones, we hypothesized that patients with IDH1 wild-type HGG would exhibit more severe NCF deficits than their IDH1 mutant counterparts.</p><p><strong>Methods: </strong>NCF was assessed by Mini Mental Status Exam (MMSE), Trail Making Test (TMT), Digit Span (DS), and Controlled Word Association Test (COWAT) tests in 147 HGG patients preoperatively.</p><p><strong>Results: </strong>Analyses between IDH1 groups revealed a significant difference on MMSE concentration component (<i>p</i> ≤ .01), DS (<i>p</i> ≤ .01), TMTB (<i>p</i> ≤ .01), and COWAT (<i>p</i> ≤ .01) scores, with the IDH1 wild group performing worse than the IDH1 mutant one. Age and tumor volume were inversely correlated with MMSE concentration component (<i>r</i> = -4.78, <i>p</i> < .01), and with MMSE concentration (<i>r</i> = -.401, <i>p</i> < .01), TMTB (<i>r</i> = -.328, <i>p</i> < .01), and COWAT phonemic scores (<i>r</i> = -.599, <i>p</i> < .01), respectively, but only for the IDH1 wild-type group. Analyses between age-matched subsamples of IDH1 groups revealed no age effect on NCF. Tumor grade showed nonsignificance on NCF (<i>p</i> > .05) between the 2 IDH1 mutation subgroups of grade IV tumor patients. On the contrary, grade III group showed a significant difference in TMTB (<i>p</i> < .01) and DS backwards (<i>p</i> < .01) between IDH1 subgroups, with the mutant one outperforming the IDH1 wild one.</p><p><strong>Conclusions: </strong>Our findings indicate that IDH1 wild-type HGG patients present greater NCF impairment, in executive functions particularly, compared to IDH1 mutant ones, suggesting that tumor growth kinetics may play a more profound role than other tumor and demographic parameters in clinical NCF of HGG patients.</p>\",\"PeriodicalId\":19234,\"journal\":{\"name\":\"Neuro-oncology practice\",\"volume\":\"10 2\",\"pages\":\"132-139\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037936/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/nop/npac077\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npac077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 2
摘要
背景:高级别胶质瘤(HGG)患者表现为神经认知功能(NCF)的可变损害。基于此，异柠檬酸脱氢酶1 (IDH1)野生型HGG比IDH1突变型HGG更具侵袭性，我们假设IDH1野生型HGG患者比IDH1突变型HGG患者表现出更严重的NCF缺陷。方法:对147例HGG患者术前采用Mini Mental Status examination (MMSE)、Trail Making Test (TMT)、Digit Span (DS)、Controlled Word Association Test (COWAT)进行NCF评估。结果:IDH1组间MMSE浓度组成(p≤0.01)、DS (p≤0.01)、TMTB (p≤0.01)、COWAT (p≤0.01)评分差异均有统计学意义，且IDH1野生组表现差于IDH1突变组。年龄、肿瘤体积与MMSE浓度组分呈负相关(r = -4.78, p < 0.01)，与MMSE浓度组分呈负相关(r = -)。401, p < 0.01)， TMTB (r = -。328, p < 0.01)，而COWAT音位评分(r = -。599, p < 0.01)，但仅适用于IDH1野生型组。对年龄匹配的IDH1组亚样本的分析显示，年龄对NCF没有影响。肿瘤分级对IV级肿瘤患者2个IDH1突变亚组NCF的影响无统计学意义(p > 0.05)。III级组在TMTB (p < 0.01)和DS倒位(p < 0.01)上在IDH1亚组间有显著差异，突变型优于野生型。结论:我们的研究结果表明，与IDH1突变型HGG患者相比，IDH1野生型HGG患者存在更大的NCF损伤，特别是在执行功能方面，这表明肿瘤生长动力学可能比其他肿瘤和人口统计学参数在HGG患者的临床NCF中发挥更深远的作用。
Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas.
Background: High-grade glioma (HGG) patients present with variable impairment in neurocognitive function (NCF). Based on that, isocitrate dehydrogenase 1 (IDH1) wild-type HGGs are more aggressive than IDH1 mutant-type ones, we hypothesized that patients with IDH1 wild-type HGG would exhibit more severe NCF deficits than their IDH1 mutant counterparts.
Methods: NCF was assessed by Mini Mental Status Exam (MMSE), Trail Making Test (TMT), Digit Span (DS), and Controlled Word Association Test (COWAT) tests in 147 HGG patients preoperatively.
Results: Analyses between IDH1 groups revealed a significant difference on MMSE concentration component (p ≤ .01), DS (p ≤ .01), TMTB (p ≤ .01), and COWAT (p ≤ .01) scores, with the IDH1 wild group performing worse than the IDH1 mutant one. Age and tumor volume were inversely correlated with MMSE concentration component (r = -4.78, p < .01), and with MMSE concentration (r = -.401, p < .01), TMTB (r = -.328, p < .01), and COWAT phonemic scores (r = -.599, p < .01), respectively, but only for the IDH1 wild-type group. Analyses between age-matched subsamples of IDH1 groups revealed no age effect on NCF. Tumor grade showed nonsignificance on NCF (p > .05) between the 2 IDH1 mutation subgroups of grade IV tumor patients. On the contrary, grade III group showed a significant difference in TMTB (p < .01) and DS backwards (p < .01) between IDH1 subgroups, with the mutant one outperforming the IDH1 wild one.
Conclusions: Our findings indicate that IDH1 wild-type HGG patients present greater NCF impairment, in executive functions particularly, compared to IDH1 mutant ones, suggesting that tumor growth kinetics may play a more profound role than other tumor and demographic parameters in clinical NCF of HGG patients.
期刊介绍：
Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
